Prolastin c 1,000 MG/20 ML VLS
Ended Awarded Last action
- Contract number
- SPE2DR26FHNU9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,273
Award facts
- Contract value 100% obligated
- $11,273.46 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $11,273.46 to DMS Pharmaceutical Group Inc. on January 14, 2026, for the supply of Prolastin C 1,000 mg/20 ml vials. Prolastin C is a therapeutic protein used to treat alpha-1 antitrypsin deficiency, a genetic disorder affecting the lungs and liver. This delivery order was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal pharmaceutical procurement. The order is scheduled for completion by February 5, 2026, with performance taking place at the contractor's headquarters in Park Ridge, Illinois.
This delivery order was issued under DMS Pharmaceutical Group Inc.'s larger Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler, holds a single-award IDC designated as contract SPE2DR valued at $499,999,999 through December 31, 2036. The PPV-G GEN V represents a $30.3 billion Defense Logistics Agency acquisition strategy designed to establish multiple regional prime vendor contractors supplying pharmaceuticals, biologics, and medical consumables to support Department of Defense military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance on numerous delivery orders since October 2025 demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FHNU9?
SPE2DR26FHNU9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 14, 2026.
How much is contract SPE2DR26FHNU9 worth?
The government has obligated $11,273 on SPE2DR26FHNU9.
Is contract SPE2DR26FHNU9 an order under another contract?
Yes. SPE2DR26FHNU9 is a delivery order under SPE2DR25D9231, an indefinite delivery contract.
Was contract SPE2DR26FHNU9 competed?
The extent of competition for SPE2DR26FHNU9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award